ZIOPHARM Oncology Inc. (ZIOP) Given Average Rating of “Hold” by Brokerages

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) has received an average recommendation of “Hold” from the six research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $5.50.

Several brokerages have recently issued reports on ZIOP. BidaskClub upgraded shares of ZIOPHARM Oncology from a “hold” rating to a “buy” rating in a research report on Thursday. Zacks Investment Research cut shares of ZIOPHARM Oncology from a “buy” rating to a “hold” rating in a research report on Thursday, December 20th. Finally, Raymond James upgraded shares of ZIOPHARM Oncology from a “market perform” rating to an “outperform” rating and set a $5.00 target price on the stock in a research report on Thursday, November 15th.

Shares of NASDAQ ZIOP traded up $0.10 during mid-day trading on Friday, hitting $3.61. 3,779,640 shares of the company’s stock traded hands, compared to its average volume of 1,618,873. The stock has a market capitalization of $563.96 million, a price-to-earnings ratio of -7.52 and a beta of 2.59. ZIOPHARM Oncology has a 1 year low of $1.56 and a 1 year high of $5.00.

A number of institutional investors have recently bought and sold shares of the stock. MSD Partners L.P. raised its position in ZIOPHARM Oncology by 222.1% in the 4th quarter. MSD Partners L.P. now owns 10,986,258 shares of the biotechnology company’s stock worth $20,544,000 after purchasing an additional 7,575,758 shares during the period. BlackRock Inc. raised its holdings in shares of ZIOPHARM Oncology by 1.3% in the third quarter. BlackRock Inc. now owns 9,289,620 shares of the biotechnology company’s stock worth $29,727,000 after buying an additional 121,880 shares during the last quarter. Vanguard Group Inc raised its holdings in shares of ZIOPHARM Oncology by 2.3% in the third quarter. Vanguard Group Inc now owns 8,783,696 shares of the biotechnology company’s stock worth $28,108,000 after buying an additional 194,441 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of ZIOPHARM Oncology by 2.3% in the third quarter. Vanguard Group Inc. now owns 8,783,696 shares of the biotechnology company’s stock worth $28,108,000 after buying an additional 194,441 shares during the last quarter. Finally, Northern Trust Corp raised its holdings in shares of ZIOPHARM Oncology by 0.5% in the fourth quarter. Northern Trust Corp now owns 1,647,754 shares of the biotechnology company’s stock worth $3,081,000 after buying an additional 8,068 shares during the last quarter. 38.07% of the stock is currently owned by institutional investors.

About ZIOPHARM Oncology

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.

Further Reading: How can you know how many shares are floating?

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.